Navigation Links
Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
Date:1/26/2011

s include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACT:

Paul Donovan508-650-8541 (office)508-667-5165 (mobile)Media RelationsBoston Scientific CorporationLarry Neumann508-650-8696 (office)Investor RelationsBoston Scientific CorporationSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporation
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY™ Drug-Eluting Coronary Stent
2. Boston Scientific Announces Agreement With Fukuda Denshi for Distribution of Cardiac Rhythm Management Products in Japan
3. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2010 Financial Results
4. Boston Scientific to Acquire Atritech
5. Boston Scientific Completes Enrollment in Clinical Trial Evaluating Next-Generation Nitinol Stent to Treat Iliac Artery Disease
6. Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
7. Boston Scientific Completes Acquisition of Sadra Medical
8. Stryker Completes Acquisition of the Neurovascular Division of Boston Scientific
9. Boston Scientific Completes Sale of Neurovascular Business
10. Boston Scientific to Present at 29th Annual J.P. Morgan Healthcare Conference
11. Boston Scientific Announces Election of Dr. Kristina M. Johnson to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015 VWR (NASDAQ: ... and solutions, announces the redesign of its global website, ... When visiting the new site, guests will enjoy enhanced ... and vivid images.  Each country site now includes: ... Z product menu; and , the ability to search ...
(Date:8/3/2015)... -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced ... Investor Conference Call and webcast at 4:30 p.m., Eastern time, ... cover an update on Merrimack,s progress as well as ... release detailing the information to be discussed on the ... 10. Investors and the general public are invited to ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. , Aug. ... naldemedine met its primary and secondary endpoints in a ... opioid-induced constipation (OIC) in adult patients with chronic non-cancer ... receptor antagonist (PAMORA). This is the third Phase III ... secondary endpoints. Study results showed that a ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... , PARSIPPANY, N.J. , Jan. 14 ... the spine market, the company has announced the addition of ... individuals filling these positions bring a deep knowledge of the ... developing strong distribution networks in their respective areas.   , ...
... , , ... Jan. 14 ImproMed, Inc. creators of the Infinity ... home delivery services on behalf of veterinarians, announce the integration ... immediately with the release of v4.5 of Infinity, veterinarians can ...
Cached Medicine Technology:Custom Spine Announces the Expansion of its Sales Management Team 2VetCentric and ImproMed, Inc.(R) Announce One-Click Home Delivery Integration 2VetCentric and ImproMed, Inc.(R) Announce One-Click Home Delivery Integration 3
(Date:8/3/2015)... ... August 04, 2015 , ... Approved provider ... line up of live courses for the month of August. , Physical therapy ... individually or by purchasing a Physical Therapy Flex package. Flex packages allow therapists ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sutter Health’s California Pacific Medical ... (COO) at CPMC. Hamila will start in her role effective immediately and will have ... has worked at CPMC and Sutter Health for about 15 years, including the past ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data ... IT to create efficiencies in healthcare information exchange, announced the release of its findings ... and Human Services (HHS) Secretary, WEDI shared survey results and recommendations ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... ruled in favor of the firm’s client Rebecca Hamsher, deciding that in accordance ... must reimburse benefits for Hamsher’s residential treatment for bulimia, depression and other mental ...
(Date:8/3/2015)... ... August 03, 2015 , ... A recent ... an overwhelming number of Hispanics believe people can positively affect their diabetes, few ... participants queried said making diet changes was important. Far fewer participants mentioned the ...
Breaking Medicine News(10 mins):Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 3Health News:Hamila Kownacki, RN Appointed as New Chief Operating Officer at CPMC 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4
... The National Patient Safety Foundation,(NPSF) today announced that ... leading health care solutions providers to work,alongside the ... their families -- all with the single convergent ... http://www.newscom.com/cgi-bin/prnh/20080307/AQF053LOGO ), "We are excited to be ...
... of Pennsylvania School of Medicine can now explain how ... in the blood stream at any one time. These ... fight infections. , "There is a steady state number ... says senior author Michael P. Cancro, PhD, Professor of ...
... with inflammatory diseases such as rheumatoid arthritis now have ... biologic disease-modifying antirheumatic drugs (DMARDs). These drugs, derived by ... of the disease rather than simply treating the symptoms. ... because a one month,s supply may cost 100 times ...
... Henri de Toulouse-Lautrec suffered, is a genetic disease characterized ... window into how joints are destroyed by arthritis. It ... cathepsin K which hampers osteoclasts (the cells that break ... poor bone resorption and dense, brittle bones. , ...
... Co-Pays, HOUSTON, Nov. 4 US Oncology today ... pharmacy, has,exceeded the $10 million mark in assisting more ... Care Advantage in August 2006., "It was important ... patient access to oral chemotherapies by easing the financial,burdens ...
... MYL ),today announced that its subsidiary Mylan ... and Drug Administration (FDA) for its,Abbreviated New Drug ... and 750 mg. Levetiracetam Tablets are the generic ... Mylan,s Vice Chairman and CEO, commented: "We are,extremely ...
Cached Medicine News:Health News:AmerisourceBergen Joins National Patient Safety Foundation Corporate Council 2Health News:Penn scientists show how body determines optimal amount of germ-fighting B cells 2Health News:Medicaid policies vary widely for rheumatoid arthritis drugs 2Health News:Genetic disorder sheds light on enzyme's role in bone metabolism 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 3Health News:Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: